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Severe acute pancreatitis (SAP) characterized by atrocious progression and numerous complications often leads to a high mortal-
ity rate due to hypermetabolism, systemic inﬂammatory response syndrome (SIRS), and multiple organs dysfunction syndrome
(MODS). Studies have revealed that both early enteral nutrition (EEN) and emodin are potent agents in the management of SAP.
However, whether the combined strategy is rational and more eﬀective than either one alone remains unknown. In this regard,
Wistar rats were treated with emodin-assisted EEN (EAEEN) through enteral nutrient tubes after induction of SAP by retrograde
infusion of 5.0% sodium taurocholate into the common pancreatic duct. Serum levels of amylase, tumor necrosis factor-alpha
(TNF-α), angiotensin II (AngII), maleic dialdehyde (MDA), glutamic pyruvic transaminase (ALT), glutamic oxaloacetic transami-
nase (AST) and C-reactive protein (CRP), intestinal secretory IgA (SIgA), pancreatic and hepatic myeloperoxidase (MPO) activity
as well as plasma levels of D-lactate and endotoxin were measured. In addition, pathologic alterations of pancreas and liver were
observed microscopically. We found that EAEEN could signiﬁcantly ameliorate these parameters and prevent pancreas and liver
from serious damage. In conclusion, Our results indicated that EAEEN could exert beneﬁcial eﬀects on experimental SAP and
obviously abate the severity of secondary hepatic injury. The combined strategy was safe and more eﬀective than either one alone
in the acute stage of SAP. This study also provided an experimental base for the clinical treatment of SAP patients with EAEEN.
Copyright © 2007 Gang Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Severe acute pancreatitis (SAP), characterized by atrocious
progression, multicomplications, and diﬃcult treatment [1–
3] is an acute abdomen that ranges from a mild illness to
a life-threatening condition. Clinically, the overall mortality
rate for SAP is approximately 38.4% [4]. In spite of decades
of intensive study, we are still in lack of etiological therapy.
SAP causes such a hypermeolic state that adequate supply of
nutrients plays a decisive role to reverse systemic malnutri-
tion, potentiate resistance against infection, block the patho-
logical deterioration, and facilitate recovery [5–7]. In the
past, it was believed that early enteral nutrition (EEN) in pa-
tientswithSAPmightexacerbatetheclinicalaswellaspatho-
logical conditions and provoke serious complications. How-
ever, therapeutic strategies have changed dramatically over
the past 20 years. The high mortality rate of SAP is often a
result of multiple organ dysfunction syndrome (MODS) and
appears to be especially related to systemic inﬂammatory re-
sponse syndrome (SIRS) or even to infections of the necrotic
pancreas. Since MODS and SIRS are apt to be facilitated
with gut mucosal dysfunction and abundant Gram-negative
bacteria as well as other gastrointestinal pathogens are com-
monlydetectedinpancreaticinfections,thegutisconsidered
to be the main source of SAP-related septic complications, so
that maintaining gut barrier is equally as important as rest-
ing the pancreas when the inﬂammation within the gland re-
solves.
Though total parenteral nutrition (TPN) has been the
standard practice for providing exogenous nutrients during
the early stage of SAP, long-term administration of TPN can
producecatheter-relatedcomplications,weakensystemicim-
munity, and induce secondary enterogenous infection. In
comparison to TPN, EEN helps enhance the immunologi-
cal and mechanical functions of intestinal mucosa, maintain
the balance of gut microﬂora, reduce oxidative stress, pre-
vent secondary infections, and improve therapeutic results.
Emodin, the main eﬀective component of rhubarb, which
is a traditional Chinese herbal medicine and has the func-
tion of purgation, heat-clearing, and detoxicating as well2 Mediators of Inﬂammation
as promoting blood circulation to remove blood stasis, has
proved to be a beneﬁcial pharmacy for SAP [8–12]. Because
of the liver’s special position in the gut circulation and the
unsubstitutable role played in body metabolism, it becomes
a major target for extrapancreatic damage of SAP. And liver
injury, in turn, deteriorates SAP and ampliﬁes the systemic
damage caused by MODS. Therefore, eﬀective prevention of
liver injury is a key to shortening the course of SAP and de-
creasing the related mortality.
EEN and emodin have been fully aﬃrmed by most schol-
ars as an important part of therapy for SAP. However, it is
still controversial what substance and dosage in EEN and
what timing and route of administration of EEN associated
with emodin are more appropriate and whether the com-
bined treatment is more eﬀective than either one alone. In
the present experiment, we tried to explore possible mecha-
nisms of EEN and emodin in the treatment of SAP as well as
its secondary hepatic injury, and to demonstrate the feasibil-
ity and eﬀectiveness of emodin-assisted early enteral nutri-
tion (EAEEN).
2. MATERIALS AND METHODS
2.1. Materials
SixtyhealthymaleWistarrats,weighing190–250g,werepur-
chased from Animal Center, the First Clinical Hospital of
HarbinMedicalUniversity(Harbin,China).Emodinwasob-
tained from Pharmacy, the First Clinical Hospital of Harbin
Medical University. Pepti-2000 variant was purchased from
Nutricia (Zoetermeer, The Netherlands). Sodium tauro-
cholate was obtained from Sigma (St. Louis, Mo, USA).
2.2. Animalmodels
Sixty male Wistar rats, housed in cages with a controlled
temperature of 26◦C and 12-hour light-dark cycles, were fed
standard laboratory chow as well as water ad libitum, and al-
lowed to acclimatize for at least a week. The rats were fasted
overnight with free access to water before experiments. Sur-
gical anesthesia was performed by intraperitoneal injection
of 1% pentobarbital sodium (40mg/kg body weight). SAP
was induced by retrograde infusion of 5.0% sodium tauro-
cholate (0.15mL/100g body weight) into the common pan-
creatic duct [13]. The “out” end of the enteral nutrient tube
wasplacedat7cmfromthefarpointofTreitzligament,while
the “in” end was dragged backward through the body wall
and ﬁxed on the back. The experimental protocol was under-
taken in accordancewith the guideline for the careand use of
laboratory animals in research and was approved by the Eth-
ical and Research Committee of the First Clinical Hospital,
Harbin Medical University.
2.3. Experimentalgroups
Sixty rats were randomly divided into four groups (n =
15) after SAP induction: control group (group A), emodin
group (group B), EEN group (group C), and EAEEN group
(group D). Control group was allowed free access to water
without any intervention; Emodin group received emodin
(3.0mg/100g body weight) through enteral nutrient tube at
12h, 22h, 32h, 42h,52h, and 62h, respectively; EEN group
received Pepti-2000 variant through enteral nutrient tube at
15h, 25h, 35h, 45h, 55h, and 65h, respectively. The en-
teral nutrient solution was continuously infused at each time
point and the dosage at 15h, 25h, and 35h was 120mL/kg
(body weight) followed by that increasing to 240mL/kg
(body weight) at 45h, 55h, and 65h; EAEEN group received
emodin (3.0mg/100g body weight) at 12h, 22h, 32h, 42h,
52h, and 62h and Pepti-2000 variant at 15h, 25h, 35h, 45h,
55h, and 65h. The dosage and infusion method of Pepti-
2000 variant at each time point in EAEEN group were the
same as those in EEN group. Both emodin and the enteral
nutrient solution were given by infusion pump.
The remaining living animals in each group were re-
anesthetized 72 hours after SAP induction using intraperi-
toneal injection of 1% pentobarbital sodium (40mg/kg body
weight).Laparotomieswereperformedandsamplesofblood
and tissues were immediately obtained.
2.4. Histopathologicexamination
A portion of the pancreatic tail and hepatic and ileal tis-
sues from each rat was incised and the pancreatic as well
as hepatic tissues were ﬁxed in 10% neutral-buﬀered forma-
lin, embedded in paraﬃn, and stained with hematoxylin and
eosin (HE) for light microscopy. Two experienced patholo-
gists who were blinded to the experimental protocol scored
the pancreatic tissue on a scale from 0 to 4 for the degrees of
edema, inﬂammation, hemorrhage, and necrosis in 20 ﬁelds.
We applied the scoring system deﬁned by Kusske et al. [14]
and the scores of each histologic examination were totaled.




The jejunum and ileum were excised and the intestinal mu-
c u sw a sc o l l e c t e dt om e a s u r et h el e v e lo fS I g Ab yr a d i oi m -
munoassay with the kit (Institute of Atomic Energy Physics,
Chinese Academy of Sciences, China). The values of MPO
activity in pancreas and liver were measured to assess poly-
morphonuclear leukocyte (PMN) inﬁltration. A portion of
the pancreatic and hepatic tissues was obtained to determine
pancreaticandhepaticMPOactivitybychromatometrywith
the kit (Invitrogen, Calif, USA) and ascitic ﬂuid was quanti-
ﬁed.
2.6. Edema
After removal, fresh samples of pancreas and ileum were
immediately weighed and dried at 100◦Cf o r2 4h o u r sa n d
reweighed. The wet-dry weight ratio of pancreas (pww/dw)
andileum(iww/dw)werecalculatedtodeterminethedegrees
of pancreatic edema and ileal edema.Gang Wang et al. 3
2.7. Laboratorytest
Bloodsampleswerecollectedfromabdominalaortaandcen-
trifuged at 3000rpm for 5 minutes. The serum was captured
and stored at −20◦C until assayed. Tumor necrosis factor-
alpha (TNF-α) and angiotensin II (AngII) were measured by
radio immunoassay with the kits (Institute of Atomic Energy
Physics,ChineseAcademyofSciences,China).Maleicdialde-
hyde (MDA), C-reactive protein (CRP) (Jiancheng Biotech
Ltd., Nanjing, China), and plasma D-lactate (Sigma, USA)
were assessed by enzymatic-spectrophotometric method.
Plasma endotoxin (Shanghai Med & Chem Institute, Shang-
hai, China) was tested by chromogenic limulus amebo-
cytelysatetechnique.Glutamic-pyruvictransaminase(ALT),
glutamic-oxaloacetic transaminase (AST), and amylase were
determined by automated HITACHI-7150 analyzer.
2.8. Statisticalanalysis
Results were expressed as mean ± standard deviation (SD).
The signiﬁcance of diﬀerences in histopathologic scores was
assessed by Kruskal-Wallis test. Other continuous data were
analyzed by factorial design ANOVA test. Statistical analysis
was ﬁnished by SPSS10.0 statistical program and diﬀerence
was considered statistically signiﬁcant when P<. 05.
3. RESULTS
Before sampling 72 hours after the induction of SAP, the ra-
t i oo fs u r v i v a lt od e a t hw a s7t o8i nc o n t r o lg r o u p ,9t o6i n
emodin group, 8 to 7 in EEN group, and 12 to 3 in EAEEN
group. Compared with control group, there were signiﬁcant
diﬀerences in the following data as described in emodin,
EEN, and EAEEN groups (P<. 05, Tables 1–4, Figures 1–5).
3.1. Macroscopicﬁndings
I ng r o u pA ,s e v e r ee d e m a ,d i ﬀuse hemorrhage, and necrosis
in pancreas were observed. The gastrointestinal tract was ob-
viously ectatic and edematous. There was much bloody as-
cites in the peritoneal cavity. Compared with group A, the
severity of macroscopic changes was signiﬁcantly abated in
groups B, C, and D.
3.2. Laboratorytest
In contrast to emodin and EEN, EAEEN signiﬁcantly re-
duced the levels of TNF-α, AngII, MDA, ALT, AST, CRP, and
amylase in serum as well as the levels of plasma endotoxin
and D-lactate (P<. 05, Tables 1, 2,a n d4, Figures 1 and 5).
Diﬀerences in these data were not considered statistically sig-
niﬁcant between group B and group C.
3.3. Edema,SIgA,MPO,andasciticﬂuid
The levels of MPO in pancreas and liver, pww/dw, iww/dw,
andtheamountofasciticﬂuidweresigniﬁcantlylower,while
the level of SIgA was obviously higher in group D than those
i ng r o u pBa n dg r o u pC( P<. 05, Tables 2, 3,a n d4, Figures























Figure 1: Changes of serum amylase levels in diﬀerent groups.
∗P<. 05 versus control group; ΔP<. 05, EAEEN group versus
Emodin group; #P<. 05, EAEEN group versus EEN group. EEN:
early enteral nutrition. EAEEN: emodin-assisted early enteral nu-
trition.


























Figure 2: Changes of the amount of ascitic ﬂuid in diﬀerent
groups.∗P<. 05 versus control group; ΔP<. 05, EAEEN group
versus Emodin group; #P<. 05, EAEEN group versus EEN group.
EEN: early enteral nutrition. EAEEN: emodin-assisted early enteral
nutrition.
2–4). However, no signiﬁcant diﬀerences were found in these
data between group B and group C.
3.4. Histopathologicexamination
The degrees of edema, inﬂammatory inﬁltration, hemor-
rhage, and necrosis and the scores of histopathologic alter-
ations in pancreas were signiﬁcantly reduced in group D as
compared with those in group B and group C (P<. 05,
Table 3, Figures 6–9). EAEEN could also attenuate the sever-
ity of secondary liver injury obviously (Figures 10–14). The
villus height of ileum was signiﬁcantly increased by EAEEN
compared with emodin and EEN (P<. 05, Table 3). There
were no signiﬁcant diﬀerences in the scores of pancreatic4 Mediators of Inﬂammation
Table 1:LevelsofMDA,TNF-α,andAngIIin4groups(EEN:earlyenteralnutrition.EAEEN:emodin-assistedearlyenteralnutrition.MDA:
maleic dialdehyde. TNF-α: tumor necrosis factor-alpha. AngII: angiotensinII).
Groups n MDA (nmol/mL) TNF-α (ng/mL) AngII (pg/mL)
Control 15 13.63 ±0.19 2.27 ±0.41 287.93 ±54.39
Emodin 15 10.15 ±1.96∗ 1.88 ±0.25∗ 200.63 ±34.57∗
EEN 15 9.94 ±0.82∗ 1.72 ±0.36∗ 219.77 ±68.79∗
EAEEN 15 6.52 ±1.07∗Δ# 1.38 ±0.17∗Δ# 159.73 ±82.85∗Δ#
∗ P<. 05, versus control group; ΔP<. 05, EAEEN group versus emodin group; #P<. 05, EAEEN group versus EEN group.
Table 2: Levels of endotoxin, iww/dw, and D-lactate in 4 groups (EEN: early enteral nutrition. EAEEN: emodin-assisted early enteral nutri-
tion. iww/dw: wet-dry weight ratio of ileum).
Groups n Endotoxin(EU/mL) iww/dw D-lactate(mmol/L)
Control 15 0.385 ±0.026 3.97 ±0.44 0.574 ±0.178
Emodin 15 0.271 ±0.015∗ 2.80 ±0.76∗ 0.417 ±0.014∗
EEN 15 0.232 ±0.037∗ 2.73 ±0.19∗ 0.391 ±0.088∗
EAEEN 15 0.114 ±0.048∗Δ# 1.71 ±0.52∗Δ# 0.282 ±0.009∗Δ#
∗ P<. 05, versus control group; ΔP<. 05, EAEEN group versus emodin group; #P<. 05, EAEEN group versus EEN group.




































Figure 3: Changes of pancreatic wet-dry weight ratio in diﬀerent
groups. ∗P<. 05 versus control group; ΔP<. 05, EAEEN group
versus Emodin group; #P<. 05, EAEEN group versus EEN group.
EEN: early enteral nutrition. EAEEN: emodin-assisted early enteral
nutrition.
histopathologic alterations as well as the ileal villus height
between group B and group C.
4. DISCUSSION
Emodin characterized by the main active monomer of
rhubarb is a derivative of anthraquinone (3-methyl-1, 6, 8-
trihydroxyanthraquinone). Studies have proved that emodin
is a potent agent in the management of clinical and exper-
imental acute pancreatitis (AP) [8]. Zhang et al. [9], and
Wu et al. [12] found emodin had signiﬁcant therapeutic ef-
fects on SAP rats by correcting intestinal ﬂora disturbances,
promoting intestinal peristalsis, inhibiting inﬂammatory cy-
tokinereleaseandpancreatinactivity,andscavengingoxygen
free radicals (OFR). Wu et al. [10] proved the mechanisms of
emodin in the treatment of SAP included modulation of ab-
normal eicosanoid metabolism, promotion of pancreatic cy-


























Figure 4: Changes of MPO activity of pancreas in diﬀerent groups.
∗P<. 05 versus control group; ΔP<. 05, EAEEN group versus
Emodin group; #P<. 05, EAEEN group versus EEN group. EEN:
early enteral nutrition. EAEEN: emodin-assisted early enteral nu-
trition. MPO: myeloperoxidase.
toprotection, and improvement of pancreatic microcircula-
tion. Kumar et al. [11] found emodin was a potent inhibitor
of nuclear factor-kappaB (NF-κB) activation as well as ex-
pression of adhesion molecules and could be useful in treat-
ing various inﬂammatory diseases. In a word, emodin has
multiple beneﬁcial eﬀects on SAP.
In our experiment, administration of EAEEN could sig-
niﬁcantly abate the severity of SAP as compared with other
groups, which was reﬂected by the reductions in levels of
serum amylase, the amount of ascitic ﬂuid, pancreatic MPO
activity, pww/dw, and the pathologic scores of pancreas. Our
results indicated that the advantages of EAEEN for the treat-
ment of SAP existed in (1) EEN alone could enhance gut im-
munity, promote hyperplasia of intestinal mucosa, improveGang Wang et al. 5
Table 3: The level of SIgA, the ileal villus height, and the pathologic scores of pancreas in 4 groups (EEN: early enteral nutrition. EAEEN:
emodin-assisted early enteral nutrition. SIgA: secretory IgA).
Groups n SIgA(ug/mL) The villus height of ileum(um) The pathologic scores
Control 15 75.44 ±20.27 299.74 ±45.27 14.13 ±0.62
Emodin 15 120.83 ±32.21∗ 438.26 ±33.79∗ 10.38 ±0.54∗
EEN 15 111.91 ±34.70∗ 446.39 ±60.71∗ 11.05 ±0.16∗
EAEEN 15 161.86 ±19.90∗Δ# 568.53 ±66.18∗Δ# 7.19 ±0.43∗Δ#
∗ P<. 05, versus control group; ΔP<. 05, EAEEN group versus emodin group; #P<. 05, EAEEN group versus EEN group.
Table 4: Levels of ALT, AST, and hepatic MPO activity in 4 groups (EEN: early enteral nutrition. EAEEN: emodin-assisted early enteral
nutrition. ALT: glutamic pyruvic transaminase. AST: glutamic oxaloacetic transaminase. MPO: myeloperoxidase).
Groups n ALT(U/L) AST(U/L) MPO(U/g)
Control 15 217.49 ±36.11 313.08 ±45.19 8.39 ±1.42
Emodin 15 177.64 ±54.30∗ 271.56 ±25.98∗ 6.24 ±1.34∗
EEN 15 170.29 ±24.57∗ 259.23 ±53.77∗ 6.09 ±0.95∗
EAEEN 15 90.95 ±55.67∗Δ# 203.12 ±36.92∗Δ# 3.95 ±0.71∗Δ#
∗ P<. 05,versus control group; ΔP<. 05, EAEEN group versus emodin group; #P<. 05, EAEEN group versus EEN group.






















versus control group; ΔP<. 05, EAEEN group versus Emodin
group; #P<. 05, EAEEN group versus EEN group. EEN: early
enteral nutrition. EAEEN: emodin-assisted early enteral nutrition.
CRP: C-reactive protein.
microcirculation of intestinal mucosa, decrease the perme-
ability of intestinal mucosa, and reduce the incidence of
translocation of intestinal bacteria; (2) Pepti-2000 variant,
which is an elemental diet with low-fat content and can be
absorbed easily, contains adequate nutritional ingredients,
scantyresidueandhaslowviscosity.AdministrationofPepti-
2000 variant by enteral nutrient tube at diﬀerent time points
conformed to the daily dietary habit, placed the pancreas at
a “full rest,” and inhibited “rebound” of the inﬂammatory
reaction; (3) emodin could clear the intestinal bacteria and
toxin, promote intestinal peristalsis and recovery of the in-
testinal function, so as to reduce the incidence of secondary
enterogenous infection. Taken together, this combined strat-
egy was methodologically more rational and purposive, with
undoubtedly higher eﬃcacy.
Figure 6: Histopathologic sections of pancreas (HE, x100), A: con-
trol group. The pancreas of control group showed extensive necro-
sis, diﬀuse edema, and massive inﬂammatory cells inﬁltration.
A vicious cycle of pancreatic microcirculatory changes
such as capillary stasis and vasoconstriction has been shown
to occur in the course of SAP [15]. Renin-angiotensin sys-
tem (RAS) is an important stress system in pancreatic micro-
circulatory disturbances. RAS in systemic circulation is acti-
vated to a great extent and produces massive angiotensinII
(AngII),whichsubsequentlycombineswithitsreceptorspre-
dominantly localized to the epithelia of pancreatic ducts,
vascular endothelia, and pancreatic acinar cells [16], results
in the strong vasoconstriction of pancreas, and aggravates
the pancreatic ischemia and necrosis in SAP. In this study,
our results proved that administration of EAEEN enhanced
colloid osmotic pressure, prevented excessive peripancreatic
andretroperitonealﬂuidexudationfollowedbyhypovolemic
shock, and inhibited the activation of pancreatic enzymes
[9, 12] so as to eliminate the main factors that induced the
abnormalactivationofRAS,furthersigniﬁcantlyreducedthe
level of serum AngII and ameliorated pancreatic microcircu-
latory disturbances.6 Mediators of Inﬂammation
Figure 7: Histopathologic sections of pancreas (HE, x100), B:
emodin group. The pancreas of emodin group showed moderate
reduction in necrosis, edema, and inﬂammatory cells inﬁltration as
compared with those in control group.
Figure 8: Histopathologic sections of pancreas (HE, x100), C: EEN
group.ThepancreasofEENgroupalsoshowedmoderatereduction
in necrosis, edema, and inﬂammatory cells inﬁltration as compared
with those in control group. EEN: early enteral nutrition.
Gut barrier dysfunction and intestinal immunosuppres-
sion are directly related to the severity of SAP, so that how
to protect the intestinal mucosa from being damaged might
play a key role in preventing bacterial and toxin transloca-
tion and deterioration of SAP. D-lactate is the indigenous
metabolic product of intestinal resident ﬂora. Normally, the
level of blood D-lactate is quite low and the measurement of
the increased plasma D-lactate level may be a useful marker
to assess the intestinal injury [17]. SIgA, the predominant
immunoglobulin present in mucosal secretions, is the ma-
jor ingredient of the intestinal immunological function on
mucosal surfaces. In this study, the levels of intestinal SIgA,
plasma D-lactate, the ileal villus height, and iww/dw showed
obvious diﬀerences in EAEEN group as compared with those
in other groups. Our data demonstrated that administration
of EEN associated with emodin could signiﬁcantly attenu-
ate the severity of gut damage and enhance the intestinal im-
munity by restoring the microecology of the intestinal ﬂora,
maintaining the intestinal epithelia integrity, abating edema
of the intestinal wall, and promoting the secretion of intesti-
nal immune substances so as to reduce the incidences of en-
terogenous infection and endotoxemia.
In SAP, bacterial and endotoxin translocation through
the damaged gut barrier is the culprit for the development
Figure 9: Histopathologic sections of pancreas (HE, x100), D:
EAEEN group. The pancreas of EAEEN group showed signiﬁcant
reduction in necrosis, edema, and inﬂammatory cells inﬁltration
as compared with those in control group, EEN group and emodin
group. EAEEN: emodin-assisted early enteral nutrition EEN: early
enteral nutrition.
Figure 10: Histopathologic sections of liver (HE, x200), A: control
group.
of secondary septic complications and a second peak of mor-
tality. Endotoxin is the lipopolysaccharide (LPS) present in
the Gram-negative bacterial wall. Abundant plasma endo-
toxin intensively remotivates mononuclear-macrophage sys-
tem and accelerates the production of many cytokines as
well as inﬂammatory mediators, which induce septic shock
and amplify SIRS followed by the development of MODS af-
ter releasing into the blood. Atrociously ampliﬁed SIRS is
a hallmark for SAP with elevated circulating proinﬂamma-
tory cytokines including tumor necrosis factor-α (TNF-α)
and interleukin-1. TNF-α is the most prominent “ﬁrst-line”
cytokine in SIRS and plays a central role in the pathogenesis
of AP and related systemic complications [18]. TNF-α can
induce inﬁltration and activation of neutrophils, upregulate
cellular adhesion molecules, promote the secretion of OFR,
initiate and aggravate the cascade of other proinﬂammatory
cytokines and inﬂammatory mediators. MPO, a member of
peroxidases secreted by neutrophils, is an indicator for the
count and activity of neutrophils.
In our study, administration of EAEEN signiﬁcantly re-
duced the levels of plasma endotoxin, serum TNF-α,a n d
MPO in pancreatic tissue, so as to inhibit both local and sys-
temicinﬂammatoryreactionaswellasoxidizingreactionand
abate the severity of pancreatic damage. We enumerated theGang Wang et al. 7
Figure 11: Histopathologic sections of liver (HE, x200), A: control
group. Figures 10 and 11 showed many inﬂammatory cells inﬁl-
tration in portal area, hepatic endothelial cells hyperplasia, vacuo-
lar degeneration, and punctate necrosis of hepatic cells in control
group.
Figure 12: Histopathologic sections of liver (HE, x200), B: emodin
group. The liver of emodin group showed few inﬂammatory cells
inﬁltrationinportalareaandtherewerenoobviouschangesinhep-
atic cells.
following explanations as the rationales: (1) emodin could
inhibit the overgrowth of pathogenic organisms including
Gram-negative bacteria in the intestinal tract [9] and accel-
erate their excretion by promoting intestinal peristalsis, so
that the direct source of endotoxin was eradicated and the
level of plasma endotoxin depressed; (2) EEN could poten-
tiate plasma protein synthesis, increase the blood perfusion
in portal system, promote hepatoenteral circulation, and en-
hance hepatic detoxiﬁcation, which in turn greatly reduced
thelevelofplasmaendotoxin;(3)EENimprovedthegutbar-
rier function and maintained the balance of gut microﬂora
so as to decrease the production of endotoxin and to prevent
it from entering the blood, which consequently abated the
remotivation of mononuclear-macrophage system, so that
the releases of TNF-α and other cytokines were reduced; (4)
emodin inhibited the activation of pancreatic enzyme [9]s o
as to prevent mononuclear-macrophage system, activated by
pancreatic enzyme after its entering the plasma, from pro-
ducing TNF-α; (5) AngII is capable of promoting the releases
of proinﬂammatory cytokines and stimulating the migration
and inﬁltration of monocytes and neutrophils [15, 19, 20].
Administration of EAEEN signiﬁcantly reduced the level of
serum AngII, which further decreased the concentration of
serum TNF-α and pancreatic MPO activity so as to attenu-
Figure 13: Histopathologic sections of liver (HE, x200), C: EEN
group. The liver of EEN group also showed few inﬂammatory cells
inﬁltration in portal area and the hepatic cells indicated no obvious
alterations.
Figure 14: Histopathologic sections of liver (HE, x200), D: EAEEN
group.Thehepatic cells showednosigniﬁcantchanges andthehep-
atic lobules were nearly in normal states in EAEEN group.
ate the severity of inﬂammation in pancreas; (6) TNF-α in-
duces aggregation and activation of neutrophils in the pan-
creas. Administration of EAEEN could signiﬁcantly reduce
blood TNF-α level, which consequently reversed this process
and abated the pancreatic inﬂammatory reaction.
Secondary liver injury (SLI) has a remarkable incidence
in SAP, and the severity of hepatocyte injury is proportional
totheseverityofSAP.Severalmechanismsareinvolvedinthe
initiationofSLI:(1)intheacutestage,massiveproinﬂamma-
tory factors excessively activate the liver Kupﬀer cells, which
then intensely release even more profactors, so that a cascade
amplifyingcycleinsideandoutsidetheliverisformed,bring-
ing heavy inﬂammatory injury to the liver; (2) TNF-α and
endotoxininducemassiveneutrophilsinﬁltrationandactiva-
tion, producing great amount of OFRs, which initiate inten-
sive lipid peroxidations aggravating liver injury; (3) intesti-
nal mucosal damage leads to a remarkable increase of endo-
toxin level in the portal circulation bringing enormous dam-
age to the liver. Sameshima et al. [21] found that LPS could
signiﬁcantly elevate serum TNF-α activity and induce more
severe liver damage in AP rats, which suggested that both
LPS and TNF-α played critical roles in the development of
secondary hepatic injury during AP. Tadao et al. [22]f o u n d
that activated neutrophils and macrophages produced large8 Mediators of Inﬂammation
amount of OFRs in SAP and they were closely involved in
the secondary liver disease. MDA is the product of lipid per-
oxidation of OFR, which indicates the amount of OFR and
indirectly reﬂects the severity of tissue damage. CRP is an
acute phase reactive protein produced by the liver especially
in the context of SAP. The increase of serum CRP is propor-
tional to the severity of hepatocyte injury. Our experiment
demonstrated that EAEEN could remarkably decrease TNF-
α,M D A ,a n de n d o t o x i nl e v e l si nt h eb l o o da n dM P Oa c t i vi ty
in the liver, so that protect the liver from the tremendous in-
ﬂammatory and oxidizing injuries brought upon by SAP, as
manifested by the decreases of ALT, AST, and CRP levels in
the blood.
In a word, administration of emodin prior to EEN
formed a ﬁrm base for subsequent EEN therapy of SAP by
clearing bacteria and toxin, promoting exsuﬄation and defe-
cation, abating abdominal distension and systemic inﬂam-
matory reaction, so that the enteral nutrient solution could
be fully absorbed. Furthermore, EEN could “compensate
for” the massive loss of nutrients caused by administration
of emodin, so they two could beneﬁt each other in combina-
tion and obviously improve the therapeutic eﬃcacy. In this
experiment, administration of emodin and EEN in the early
stageofSAPwassafeandrational,andthecombinedstrategy
was more eﬀective than either one alone. Our results showed
that administration of EAEEN could control multiple dete-
r i o r a t i n gf a c t o r so fS A Pa n dp r o v i d e da ne ﬀective treatment
for SAP and its secondary hepatic injury by protecting in-
testinal mucosal barrier, enhancing body immune compe-
tence, inhibiting systemic inﬂammatory reaction and revers-
ing microcirculatory dysfunction, and so forth. This study
suggested a broad potential value for EAEEN in the clinical
treatment of SAP. However, further studies are needed to de-
termine whether administration of EAEEN can also protect
other organs from being damaged in SAP.
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